# Junta clínica — PT-pseudo_b6db06db35d7 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_b6db06db35d7",
  "pid": "PT-pseudo_b6db06db35d7",
  "task": 1,
  "psa": 5.2,
  "age": 57,
  "months": 1,
  "pirads": "5",
  "psad": 0.11,
  "psav": 1.38,
  "psap": 3.2,
  "vol": 47.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8199149,
  "medhx": "Osteoarthritis, Benign prostatic hyperplasia",
  "meds": "tamsulosin",
  "notes": "PSA 5.2 ng/mL. PI-RADS 5. PSAD 0.11. Prostate volume 47 mL. csPCa 0.82.",
  "pmhx": [
    "Osteoarthritis",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "79 kg",
    "height": "182 cm",
    "bmi": "23.8",
    "bp": "119/89 mmHg",
    "hr": "73 bpm",
    "smoking": "Non-smoker",
    "last_dental": "6 mo ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "13 Jan 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment of a recent PSA climb to 5.2 ng/mL alongside a newly identified PI-RADS 5 MRI finding and a previously Positive prior biopsy result."
    },
    {
      "s": "History",
      "t": "A 57-year-old non-smoker who lives independently, this widowed semi-retired musician carries a background of benign prostatic hyperplasia currently treated with tamsulosin. His initial urological workup began in early 2023 when a PSA reading of 2.3 ng/mL was noted, ultimately yielding a Positive prior biopsy. He experiences moderate lower urinary tract complaints, characterized by nocturia occurring twice each night and a diminished stream, yielding an IPSS of 11. Past medical history includes knee osteoarthritis and stable chronic obstructive pulmonary disease, the latter prompting a pulmonary function assessment earlier this month. He walks 45 minutes daily, limits alcohol to roughly 10 units per week, and enjoyed a stable cardiology check in autumn 2024. He explicitly denies bone discomfort, haematuria, or unaccounted weight reduction, citing only the 60-minute train journey to the clinic as a notable daily logistical hurdle."
    },
    {
      "s": "Physical examination",
      "t": "Per rectum: DRE confirms a normal examination with a symmetrically enlarged prostate, smooth and firm consistency, and absent nodules or asymmetry. General assessment shows stable vitals (BP 119/89 mmHg, HR 73 bpm) with no abdominal masses or lymphadenopathy. Nutritional status appears adequate, and independent ambulation is noted, accompanied by a mild antalgic gait attributable to established osteoarthritis."
    }
  ],
  "occupation": "musician (semi-retired)",
  "marital": "Widowed",
  "living": "Lives alone",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [
    "Pulmonary function test — known COPD follow-up",
    "Cardiology — annual review (stable, autumn 2024)"
  ],
  "alcohol": "10 units / week",
  "exercise": "Walking 45 min/day",
  "ipss": "IPSS score: 11/35 (moderate LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "Spaarne Gasthuis (Haarlem)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_b6db06db35d7
Task: 1

Encounter: Urology - outpatient on 13 Jan 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 57-year-old male
  - PSA: 5.2 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.11 ng/mL²
  - PSA velocity: 1.38 ng/mL/yr
  - Prior PSA: 3.2 ng/mL
  - Prostate volume: 47.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8199149 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 5.2 ng/mL. PI-RADS 5. PSAD 0.11. Prostate volume 47 mL. csPCa 0.82.

Vitals: weight 79 kg, height 182 cm, BMI 23.8, BP 119/89 mmHg, HR 73 bpm. Smoking: Non-smoker.

Chief complaint: Assessment of a recent PSA climb to 5.2 ng/mL alongside a newly identified PI-RADS 5 MRI finding and a previously Positive prior biopsy result.

History: A 57-year-old non-smoker who lives independently, this widowed semi-retired musician carries a background of benign prostatic hyperplasia currently treated with tamsulosin. His initial urological workup began in early 2023 when a PSA reading of 2.3 ng/mL was noted, ultimately yielding a Positive prior biopsy. He experiences moderate lower urinary tract complaints, characterized by nocturia occurring twice each night and a diminished stream, yielding an IPSS of 11. Past medical history includes knee osteoarthritis and stable chronic obstructive pulmonary disease, the latter prompting a pulmonary function assessment earlier this month. He walks 45 minutes daily, limits alcohol to roughly 10 units per week, and enjoyed a stable cardiology check in autumn 2024. He explicitly denies bone discomfort, haematuria, or unaccounted weight reduction, citing only the 60-minute train journey to the clinic as a notable daily logistical hurdle.

Physical examination: Per rectum: DRE confirms a normal examination with a symmetrically enlarged prostate, smooth and firm consistency, and absent nodules or asymmetry. General assessment shows stable vitals (BP 119/89 mmHg, HR 73 bpm) with no abdominal masses or lymphadenopathy. Nutritional status appears adequate, and independent ambulation is noted, accompanied by a mild antalgic gait attributable to established osteoarthritis.

Patient info: musician (semi-retired); Widowed; Lives alone.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 10 units / week; exercise Walking 45 min/day; IPSS score: 11/35 (moderate LUTS).

Recent other appointments: Pulmonary function test — known COPD follow-up; Cardiology — annual review (stable, autumn 2024).
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.57
  uncertainty  +/- 0.10 epistemic (95% band 0.36-0.77); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 2 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 57 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 5.2 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 47 mL (1% of my signal; from log_vol, vol) · PSA density = 0.11 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.82 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  important  prior biopsy = Positive
  noted      age = 57 · DRE = Normal · PSA = 5.2 ng/mL · prostate volume = 47 mL · PSA density = 0.11 · PI-RADS = 5 · comorbidity = 2 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: uncertain — none of my three panel rules applies; the fact that would settle it — the documented prior grade — lives in the notes, not on the panel

## Intervención 5 — EXPERT-EXPERIENCE

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

I recall 49 men I have seen in this same situation (Positive prior biopsy). The 3 most similar patients, and what the reading urologist did:
  1. distance 1.03: PI-RADS 5, PSA 4.53, PSAD 0.12, age 50, DRE Normal -> BIOPSY (clear). He wrote: "young patient with pirads5= high probability of significant prostate cancer and only one prev biopsy, increasing PSA. indicated with one more confirmatory biopsy to excl…"
  2. distance 1.49: PI-RADS 5, PSA 12.0, PSAD 0.28, age 61, DRE Normal -> DEFER (borderline). He wrote: "Young patient with elevated PSA (>10), elevated PSA density, PIRADS5 and ISUP GG2 disease -> low threshold for recommending curative treatment. IF patient does not want…"
  3. distance 1.71: PI-RADS 5, PSA 8.7, PSAD 0.4, age 54, DRE Normal -> BIOPSY (uncertain). He wrote: "Young patient with high risk disease, should be recommended curative treatment. Biopsy report congruent with MRI, probably caught the index cancer at diagnosis. Highrisk…"

PRECEDENT: BIOPSY (weighted vote 0.70 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What my professional experience contributes: it shows what this urologist looks at and how he phrases the call. These memories do not establish facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  important  prior biopsy = Positive · age = 57 · PSA = 5.2 ng/mL · PSA density = 0.11 · PI-RADS = 5
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 47 mL · csPCa probability = 0.82 · comorbidity = 2 on the problem list
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  important  prior biopsy = Positive · age = 57 · PSA = 5.2 ng/mL · PI-RADS = 5
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 47 mL · PSA density = 0.11 · comorbidity = 2 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guidelines discuss using a risk-adapted matrix involving PI-RADS score, PSA density, and prior biopsy status to guide the decision for biopsy. The guideline suggests that for patients with a PI-RADS score of 1-3 and a low-risk profile (PSA-D < 0.15ng/mL/cc, negative DRE, no family history, no ASAP or ISUP1 cancer at prior biopsy), biopsy could be avoided in 99 men while missing ISUP GG 2 cancers in only six men.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your bid of BIOPSY p(biopsy) = 0.57 is not settled by the guideline, as the guideline suggests avoiding biopsy in low-risk profiles. The guideline treats the variable csPCa probability as context, whereas the guideline suggests that if the patient has a low-risk profile, biopsy could be avoided. The guideline requires the prior grade of the prior biopsy to be established, which is a fact the panel does not represent. The guideline needs the documented prior grade of the prior biopsy to determine the next step.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: the PSA velocity is a variable that the guideline makes decisive, and the guideline suggests that a rising PSA velocity might influence the decision.
laboratory_results - the PSA density: the PSA density is a variable that the guideline makes decisive, and the guideline suggests that a low PSA density is a factor in risk stratification.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case hinges entirely on establishing the grade of the prior biopsy and the PSA velocity, as the EAU guideline suggests avoiding biopsy in low-risk profiles.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size and zone, extraprostatic extension, and comparison against an earlier study inform the decision?
  psa_trend (get_psa_trend) -> Does the PSA velocity influence the decision according to the guideline?
  previous_notes (get_previous_notes) -> What is the grade of the prior biopsy (Gleason or ISUP), the number and dates of biopsy sessions, and whether he is on a surveillance protocol with a confirmatory biopsy due?
  laboratory_results (get_lab_results) -> Does the PSA density factor into the risk stratification according to the guideline?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the grade of the prior biopsy?
  Q2. What is the PSA velocity?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Prostate Multiparametric MRI | Facility: Spaarne Gasthuis, Haarlem | Date: 08 Jan 2025
Does the lesion size and zone, extraprostatic extension, and comparison against an earlier study inform the decision?
The lesion is described as a "distinct, hypointense focus within the right mid peripheral zone, spanning 12 x 9 mm." It is compared against a "previously positive biopsy result."

psa_trend
Does the PSA velocity influence the decision according to the guideline?
The PSA velocity shows a rise from "0.6" (Jan 2023) to "3.3" (Jan 2024) to "5.2" (Jan 2025).

previous_notes
What is the grade of the prior biopsy (Gleason or ISUP), the number and dates of biopsy sessions, and whether he is on a surveillance protocol with a confirmatory biopsy due?
The grade of the prior biopsy is "Gleason 3+3" from a biopsy session in "July 2023". He is not explicitly stated to be on a surveillance protocol with a confirmatory biopsy due.

laboratory_results
Does the PSA density factor into the risk stratification according to the guideline?
The PSA density is "0.11 ng/mL²".

WHAT I DID NOT OPEN
family-history anamnesis, as it was not explicitly requested by the moderator and the core decision hinges on the established facts from the other documents.

WHAT THIS SUPPORTS
FOR sampling this patient now
The PI-RADS score of 5 is high risk.
The prior biopsy result was "Gleason 3+3".

AGAINST sampling this patient now
The EAU guideline suggests avoiding biopsy in low-risk profiles, which is not yet definitively established by the prior biopsy grade.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 5.20 ng/mL over 3 points spanning 24 months; velocity +2.30 ng/mL per year; doubling time about 8 months.
PROJECTION at 6 months: 6.2 ng/mL, conformal 95% band 1.8-21.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 5.2 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: uncertain — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.63
  uncertainty  +/- 0.10 epistemic (95% band 0.43-0.83), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      DRE = Normal (5% of my signal; from dre_suspicious) · PSA = 5.2 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 47 mL (4% of my signal; from log_vol, vol) · PSA density = 0.11 (0% of my signal; from psad_calc) · comorbidity = 2 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, csPCa probability
CONFIDENCE: borderline — 'supports' tier; out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.57  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.63  ('supports' tier, fusion_full; weight 3.0)
  EXPERT-EXPERIENCE  BIOPSY, p(biopsy)=0.70  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: GG 1 ("Gleason 3+3")

RULE THAT FIRED: documented prior grade GG 1 (Gleason 3+3) — carried by documented grade.
PANEL ANSWER: BIOPSY. A documented GG 1 in a man under surveillance is what a confirmatory biopsy is for: the reading urologist re-sampled 3 of the 4 labelled men with a recorded GG 1.

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:IMP E2:—            -> important
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          57                           E1:not E3:— cohort:not library:IMP E2:—              -> important
  dre          Normal                       E1:not E3:not cohort:not library:not E2:—            -> noted
  psa          5.2 ng/mL                    E1:not E3:not cohort:not library:IMP E2:not          -> important
  vol          47 mL                        E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.11                         E1:not E3:not cohort:not library:IMP E2:—            -> noted
  cspca        0.82                         E1:not E3:— cohort:— library:not E2:—                -> not_used
  pirads       5                            E1:not E3:IMP cohort:not library:IMP E2:—            -> important
  comorbidity  2 on the problem list        E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened appear to have answered the moderator's questions. The `previous_notes` document states the prior biopsy grade is "Gleason 3+3" from a July 2023 session, and the `psa_trend` document shows a PSA velocity rising from "0.6" to "5.2" over two years.

ALIGNMENT WITH THE PANEL
The retrieved evidence aligns with the PANEL-PROTOCOL's answer of BIOPSY. The protocol states that a documented prior grade of GG 1 (Gleason 3+3) in a patient under surveillance is what a confirmatory biopsy is for, which is the basis for the panel's decision.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the grade of the prior biopsy? Answered by the `previous_notes`: "Gleason 3+3".
Q2. What is the PSA velocity? Answered by the `psa_trend`: a rise from "0.6" (Jan 2023) to "5.2" (Jan 2025).

WHAT CARRIES WEIGHT, AND WHY
prior biopsy: decisive: Positive (Gleason 3+3) because the panel rule fired on this documented grade. I agree with the PANEL-PROTOCOL's level.
psa: important: 5.2 ng/mL because the rising PSA velocity is a variable the guideline makes decisive, and the trend is noted. I agree with the PANEL-PROTOCOL's level.
My confidence in the record as it stands is clear, as all required information to satisfy the panel's decision has been retrieved.

MY SUGGESTION TO THE CHAIR
The panel's position to proceed with biopsy is supported by the retrieved facts, specifically the documented prior biopsy grade of Gleason 3+3, which triggers the protocol rule.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

PI-RADS 5 with prior Gleason 3+3 biopsy warrants further tissue sampling. The prior biopsy grade is documented as Gleason 3+3, and the PSA is rising from 0.6 to 5.2 ng/mL. While the prior grade is low-risk, the PI-RADS 5 finding necessitates confirmation. Delaying biopsy for one year and re-sampling is an alternative plan.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
